

FDA-approved PD-1 and PD-L1 inhibitors

Several monoclonal antibodies that bind to programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are approved by the U.S. Food and Drug Administration (FDA) for specific types of cancer. This table is not all-inclusive; clinical trials are ongoing for a number of tumors.

PD-1 inhibitors	FDA-approved cancer indications
-----------------	---------------------------------

Pembrolizumab	<ul style="list-style-type: none">• Advanced melanoma• Cervical• Endometrial• Esophageal• Gastric• Head and neck• Hepatocellular• Hodgkin's lymphoma• Merkel cell carcinoma• Non-small cell lung• Renal cell• Small cell lung• Urothelial
Nivolumab	<ul style="list-style-type: none">• Advanced melanoma• Colorectal• Head and neck• Hepatocellular• Hodgkin's lymphoma• Non-small cell and small cell lung• Renal cell• Urothelial
Cemiplimab	<ul style="list-style-type: none">• Advanced cutaneous squamous cell carcinoma

PD-L1 inhibitors

Atezolizumab	<ul style="list-style-type: none">• Breast• Non-small cell lung and small cell lung• Urothelial
Avelumab	<ul style="list-style-type: none">• Merkel cell carcinoma• Renal cell• Urothelial
Durvalumab	<ul style="list-style-type: none">• Urothelial• Non-small cell lung